Will lower drug prices jeopardize drug research? A policy fact sheet

American Journal of Bioethics

Volumn 4, Issue 1, 2004, Pages W1-W4

  Light, Donald W ^a   Lexchin, Joel ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CANADA; COST CONTROL; DRUG COST; DRUG INDUSTRY; ECONOMICS; EUROPE; FEE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE AND PUBLIC HEALTH; HUMAN; MEDICAL RESEARCH; PHARMACOECONOMICS; UNITED KINGDOM; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; HEALTH CARE AND PUBLIC HEALTH;

BIOMEDICAL RESEARCH; CANADA; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EUROPE; FEES, PHARMACEUTICAL; GREAT BRITAIN; HUMANS; PRESCRIPTION FEES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 3142657513     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1162/152651604773067488     Document Type: Article

References (36)

1. Baker, D., and N. Chatani. 2002. Promoting good ideas on drugs: The relative efficiency of patent and pubic support for bio-medical research. In The Transatlantic Consumer Dialogue Committee on Intellectual Property. Washington, D.C.
2. Barnett, A. 2003. Revealed: How drug firms ’hoodwink’ medical journals. Pharmaceutical giants hire ghost writers to produce articles, then put doctors’ names on them. The Observer, 7 December, 15
3. Barral, P. E. 1996. 20 Years of Pharmaceutical Research Results Throughout The World: 1975-94. Paris: Rhone-Poulenc Rorer Foundation.
4. Bassand, J-P., J. Martin, L. Ryden, and M. Simoons. 2002. The need for resources for clinical research. Lancet 360:1866-68.
5. Bekelman, J. E., Y. L. Mphil, and C. P. Gross. 2003. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. Journal of the American Medical Association 289:454-65.
6. Business Week editors. 2003. Drug R&D: Must Americans always pay? Business Week, 13 October.
7. Department of Health (UK). 1999. The Pharmaceutical Price Regulation Scheme. London: Department of Health (UK), 1-45.
8. DiMasi, J. A., R. W. Hansen, and H. Grabowski. 2003. The price of innovation: new estimates of drug development costs. Journal Of Health Economics 22:151-185.
9. DiMasi, J. A., R. W. Hansen, H. G. Grabowski, and L. Lasagna. 1991. Cost of innovation in the pharmaceutical industry. Journal Of Health Economics 10:107-142.
10. European Federation of Pharmaceutical Industries and Associations. 2000. The Pharmaceutical Industry In Figures. Brussels, Belgium: European Federation of Pharmaceutical Industries and Associations.
11. Families USA. 2001. Off the Charts: Pay, Profits and Spending by Drug Companies. Washington, D.C.
12. Families USA. Families USA. 2003. Out of Bounds: Rising Prescription Drug Prices for Seniors. Washington, D.C.: Families USA.
13. Fletcher, R. H. 2003. Adverts in medical journal: Caveat lector. Lancet 361:10-11.
14. Harris, G. 2003. Where are all the new drugs? The New York Times, 5 October, BU1, 8.
15. Kaitin, K. I., and E. M. Healy. 2000. The new drug approvals of 1996, 1997, and 1998: Drug development trends in the user fee era. Drug Information Journal 34:1-14.
16. Laing, R., B. Waning, A. Gray, et al. 2003. 25 years of WHO essential medicines list: Progress and challenges. Lancet 361:1723-29.
17. Lexchin, J., L. A. Bero, B. Djulbegovic, and O. Clark. 2003. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal; 326:1167-70.
18. Love, J. 2003. Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines. Washington, D.C.: Consumer Project on Technology.
19. McClellan, M. 2003. Speech before First International Colloquium on Generic Medicine. U.S. Food and Drug Administration, 25 September.
20. Moyers, B. 2002. Science for Sale. In: Moyers B, ed. NOW with Bill Moyers. New York: Public Affairs Television.
21. National Institute for Health Care Management. 2000. Prescription Drugs and Intellectual Property Protection. Washington, D.C.: National Institute for Health Care Management.
22. National Institute for Health Care Management, Research and Education Foundation. 2002. Changing Patterns of Pharmaceutical Innovation. Washington, D.C.: National Institute for Health Care Management, Research and Education Foundation, 1-23.
23. National Science Foundation. 2003. Research and Development in Industry: 2000. Arlington, VA: National Science Foundation, Division of Science Resources Statistics.
24. Patented Medicine Prices Review Board. 2002. A Comparison of Pharmaceutical Research and Development Spending. Ottawa, Canada: Patented Medicine Prices Review Board.
25. Peterson, M. 2002. Madison Ave. has growing role in the business of drug research. The New York Times, 22 November.
26. Pharmaceutical Price Regulation Scheme (UK). 2002. Sixth Report to Parliament. London: Pharmaceutical Price Regulation Scheme, Department of Health (UK).
27. Pharmaceutical Research and Manufacturers of America. 2002. Pharmaceutical Industry Profile 2002. Washington DC: Pharmaceutical Research and Manufacturers of America.
28. Prescrire International. 2003. A review of new drugs and indications in 2002: Financial speculation or better patient care? Prescrire International 12(64): 74-77.
29. Productivity Commission of Australia. 2001. International Pharmaceutical Price Differences: Research Report. Melbourne, Australia: Productivity Commission of Australia.
30. Safire, W. 2003. The donut’s hole. The New York Times, 27 October, A21.
31. Sager, A., and D. Socolar. 2003. Lower U.S. Prescription Drug Prices Are Vital to Both Patients and Drug Makers - But instead, U.S. Prices Have Been Rising Rapidly Relative to Those in Other Wealthy Nations. Boston: Health Reform Program, Boston University School of Public Health.
32. The Global Alliance for TB Drug Development. 2001. Economics of TB Drug Development. New York: The Global Alliance for TB Drug Development.
33. Villanueva, P., S. Peiro, J. Librero, and I. Pereiro. 2003. Accuracy of pharmaceutical advertisements in medical journals. Lancet 361:27-32.
34. Wazana, A. 2000. Physicians and the pharmaceutical industry. Journal of the American Medical Association 283:373-380.
35. Williams, D. 2003. Stealth merger: Drug companies and government medicalmedical research. Los Angeles Times, 7 December.
36. Wolpe, P. R. 2003. Not just how, but whether: Revisiting Hans Jonas. The American Journal of Bioethics 3(4):vii-viii.